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The chemokine receptor CXCR4 belongs to the large superfamily of G protein-coupled receptors, and is directly involved in a number of
biological processes including organogenesis, hematopoiesis, and immune response. Recent evidence has highlighted the role of CXCR4 in a
variety of diseases including HIV, cancer, and WHIM syndrome. Importantly, the involvement of CXCR4 in cancer metastasis and WHIM
syndrome appears to be due to dysregulation of the receptor leading to enhanced signaling. Herein we review what is currently known regarding
the regulation of CXCR4 and how dysregulation contributes to disease progression.
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four groups (CXC, CC, C, and CX3C) based on the position of
the first two cysteines [1]. Chemokine receptors belong to the G
protein-coupled receptor (GPCR) superfamily and couple to the
pertussis toxin sensitive Gi proteins [2]. In general, chemokines/⁎ Corresponding author.
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doi:10.1016/j.bbamem.2006.11.002chemokine receptors exhibit promiscuity, being able to bind
multiple receptors/ligands, though 6 of the 18 chemokine
receptors bind a single ligand [3]. One of the best studied
chemokine receptors is CXCR4, primarily due to its role as a co-
receptor for HIV entry [4] as well as its ability to mediate the
metastasis of a variety of cancers [5].
CXCR4 is a 352 amino acid rhodopsin-like GPCR and
selectively binds the CXC chemokine Stromal Cell-Derived
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alternatively spliced isoforms of SDF have been identified.
SDF-1α is an 89 amino acid protein that is the predominantly
expressed form of SDF-1 while SDF-1β contains a four amino
acid extension at the carboxyl terminus [7]. SDF-1α and β bind
to CXCR4 with a comparable affinity (Kd of 7.5 and 13.7 nM,
respectively) [8]. Recently, an additional four splice variants
that contain 30 (SDF-1γ), 31 (SDF-1δ), 1 (SDF-1ε), and 51
(SDF-1ϕ) amino acid extensions at the carboxyl terminus
compared to SDF-1α have been identified [9]. These isoforms
are functional and have a differential tissue distribution,
however, their functional significance is currently unknown.
Mice that lack either SDF-1 or CXCR4 exhibit an almost
identical phenotype of late gestational lethality and defects in B
cell lymphopoiesis, bone marrow colonization, and cardiac
septum formation [10,11]. These and other studies reveal that
CXCR4 is essential for development, hematopoiesis, organo-
genesis, and vascularization [10–15], in addition to functioning
as a classical chemokine receptor in the adult [16,17].
As a number of reviews have recently been published
highlighting CXCR4 as a target in HIV [18–20] and its role in
cancer metastasis [5,21–23], this review will focus on what is
known regarding those factors that shape signaling, receptor
regulation, and receptor expression, and how dysregulation of
these pathways may contribute to disease progression.
1. Regulation of CXCR4 expression and function
1.1. Transcriptional control of CXCR4
In order to understand the role of CXCR4 in disease, a
fundamental understanding of the factors regulating expression
is critical. While CXCR4 was initially cloned from leukocytes
[24,25], it has since been shown to be expressed in a number of
tissues in addition to cells of hematopoietic lineages [26]. The
promoter region of CXCR4 contains a number of predicted
regulatory consensus sequences [27–29], however, the basal
transcription is mainly controlled by the opposing actions of
two transcriptional regulators. Functional characterization of the
CXCR4 promoter has revealed that Nuclear Respiratory Factor-
1 (NRF-1) is the major transcription factor positively regulating
the transcription of CXCR4 [28,29], although a potential role
for an additional transcription factor, SP-1, has also been
suggested [29]. This work also defined a negative regulatory
element upstream (near position − 300 of the transcriptional
start site) that may be mediated by Ying Yang 1 (YY1) [30].
In addition to the basal regulation of CXCR4 transcription, a
number of signaling molecules also have been shown to affect
CXCR4 transcription. For example, the expression of CXCR4
can be increased as a result of intracellular second messengers
such as calcium [28] and cyclic AMP [31], by the cytokines
interleukin-2 (IL-2) [28], IL-4 [32], IL-7 [32], IL-10 [33], IL-15
[32], TGF-1β [33], and simultaneous CD3 and CD28 engage-
ment [28], and by growth factors such as basic fibroblast growth
factor (bFGF) [34,35], vascular endothelial growth factor
(VEGF) [35], and epidermal growth factor (EGF) [36]. On the
other hand, inflammatory cytokines such as tumor necrosisfactor-α (TNF-α) [34,37,38], interferon-γ (INF-γ) [37], and IL-
1β [37] have all been shown to attenuate CXCR4 expression.
These data clearly show that there is dynamic regulation of
CXCR4 transcription as the result of physiological stimuli. Of
additional interest are those factors that regulate CXCR4
expression and affect disease progression, such as modulating
HIV infection. Alterations in NRF-1 or YY1 activity can lead to
an increase or decrease in transcription of CXCR4, respectively,
which certain viruses appear to have taken advantage of. The
human T lymphotropic virus type I transactivator Tax protein
interacts with and enhances NRF-1 activity, which in infected
individuals may enhance susceptibility to HIV infection or
disease progression [39]. In contrast, individuals infected with
human herpes virus 6 have a decrease in cell surface expression
of CXCR4 [40]. Investigation into the underlying mechanism
has revealed that there is an increase in YY1 binding through a
decreased association with c-Myc, a natural suppressor of YY1
activity [41].
1.2. Regulation of CXCR4 protein expression
A number of co-translational modifications contribute to the
expression and function of CXCR4. Within the extracellular
domain of CXCR4, there are two potential N-linked glycosyla-
tion sites, Asn11 and Asn176 [42]. Both sites undergo
glycosylation when CXCR4 is expressed in Sf9 insect cells
[43], however, only Asn11 appears to be glycosylated in
mammalian cells [44]. SDF and the HIV-1 glycoprotein gp120
bind to a non-overlapping region of the N-terminus of CXCR4
[45–50] and glycosylation has opposing effects on each
process. Mutation of Asn11 to glutamine leads to enhanced
CD4-dependent binding of both CXCR4-specific and duel
tropic (CCR5 and CXCR4) HIV-1 isolates [46,51,52]. Con-
versely, mutation of Asn11 to glutamine [52] or leucine [43]
disrupts SDF binding and diminishes signal transduction [52].
Thus, glycosylation of CXCR4 is important for SDF binding
and helps to inhibit the use of CXCR4 as an HIV-1 co-receptor.
CXCR4 has also been shown to undergo tyrosine sulfation, a
modification catalyzed by tyrosyl protein sulfotransferase
within the trans-golgi network. There are three extracellular
tyrosines in CXCR4 that are modified by sulfation, Tyr7, Tyr12,
and Tyr21, with Tyr21 accounting for the majority of sulfate
incorporation [53]. Functionally, tyrosine sulfation of CXCR4
doesn't regulate co-receptor usage by HIV-1 [53] as is observed
with CCR5 [54], however, similar to CCR2b [55], CCR5 [56],
and CX3CR1 [57], this is an important modification for ligand
binding [53]. Indeed, the structural basis for sulfotyrosine–SDF
interaction reveals that sulfotyrosine 21 binds to a specific site
on SDF-1 that includes Arg47 [58]. An additional N-terminal
modification that has been identified in CXCR4 is addition of a
chondroitin sulfate chain at serine 18, although no functional
consequence of this modification has been identified [53].
1.3. Oligomerization
An emerging theme in GPCR signaling is the formation of
homo- and heterodimers [59]. CXCR4 exhibits significant
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differential glycosylation, or the formation of oligomers
[60,61]. It has been suggested that CXCR4 has the ability to
homodimerize in the absence of ligand [62–65], an event that
most likely occurs soon after protein translation [62]. However,
two reports suggest that SDF can also enhance dimerization
[65,66]. There have also been reports of CXCR4 forming
heterodimers with CCR2 and CD4, which may affect the
functionality of CXCR4 as a co-receptor for HIV [64,65,67–
69]. While some studies suggest that CXCR4 does not
heterodimerize with CCR5 [62,63], CD4+ cells isolated from
patients with a CCR5Δ32 mutant, a loss-of-function mutation
that prevents cell surface expression of CCR5, have reduced
expression of CXCR4 [70]. Moreover, these studies show that
CCR5Δ32 and CXCR4 can interact resulting in reduced cell
surface expression of CXCR4 and enhanced resistance to HIV
infection [70].
The functional consequences of homo- or heterodimerization
are currently not well understood. However, it has been
suggested that homodimerization of CXCR4 is necessary to
elicit G protein independent activation of JAK/STAT as well as
enhance the response of CXCR4 to SDF (see below).
Heterodimerization may be a means of achieving an additional
level of regulation. For example, it has recently been proposed
that non-agonist occupied CCR5 may be phosphorylated by
GRK2 activated as a result of heterodimer formation and
ligation of C5a [71]. Taken together, homo- and hetero-
oligomerization of CXCR4 may be a way of regulating
signaling while also allowing for alternative, non-classical,
signaling pathways upon activation.
2. Regulation of CXCR4 signaling
2.1. SDF binding
The interaction between SDF and CXCR4 has been
proposed to occur through a two-step process [72]. The initial
interaction between residues 12–17 of SDF and 2–36 of
CXCR4 are believed to result in a conformational change in
the receptor [73]. This conformational change facilitates
interaction between the first eight amino acids of SDF and
an exposed binding pocket in CXCR4 that involves residues
in both the second (Asp187) and third (Glu268) extracellular
loops [45,50]. As this interaction requires the integrity of both
SDF and CXCR4, it is not surprising that proteases are able to
inhibit this interaction. During an inflammatory response,
neutrophil released cathepsin G and neutrophil elastase have
the ability to inactivate SDF by cleaving the N-terminal
residues necessary for interacting with CXCR4 [74,75].
Additionally, the widely expressed cell surface protease
dipeptidase 26 (CD26) is also able to cleave and inactivate
SDF [76–78]. To date, only neutrophil elastase has been
shown to cleave the N terminal domain of CXCR4, effectively
disrupting interaction with SDF [75]. Therefore, inflammatory
responses promote the release of factors that positively and
negatively regulate the receptor. When taken together, these
data highlight the exquisite interplay between a variety offactors that are able to shape and influence the SDF-CXCR4
signaling axis, ensuring that the proper physiological response
is elicited.
SDF-1 is also able to interact with glycosaminoglycans, such
as heparin sulfate, and is most likely immobilized in vivo
allowing for gradient formation [79,80]. Furthermore, this
association may induce the oligomerization of SDF-1 [81], a
phenomenon observed at high SDF-1 concentrations [72,82–
84], that may promote CXCR4 oligomerization and enhanced
function. In fact, it has been shown that the combination of
glycosaminoglycans and SDF-1 enhanced migration when
compared to SDF alone [85]. Moreover, SDF-1 mediated
inhibition of HIV X4 isolates was enhanced in the presence of
heparin sulfate [86].
It may also be possible to sensitize CXCR4 to have a greater
response to lower SDF-1 concentrations. Recent evidence
suggests that products released during inflammatory responses
[87] or platelet activation [88,89] “prime” the SDF response
enhancing hematopoietic stem/progenitor cell migration at
lower SDF concentrations [87–89]. This phenomenon may be
the result of changing the membrane localization of CXCR4
through incorporation into lipid rafts [89]. A number of studies
have suggested that lipid raft localization is required for proper
function of CXCR4 [90–92] and recently it has been shown that
SDF stimulation promotes the incorporation of Src tyrosine
kinases, focal adhesion kinase, PI3 kinase and the small G
protein Rac into lipid rafts [89]. This agonist promoted
clustering of receptor and effectors into lipid rafts might be a
way of ensuring that the proper signaling pathways are
activated.
2.2. G protein signaling
Upon activation of CXCR4, a number of signaling pathways
are activated leading to a variety of biological responses (Fig. 1)
[93]. As CXCR4 couples to the Gi family of proteins, the use of
pertussis toxin (PTX), which ADP-ribosylates Gαi and inhibits
GPCR/Gi coupling, is a useful tool to delineate pathways that
are G protein-dependent and-independent. To date, the majority
of signaling pathways and biological outcomes of CXCR4
activation are PTX-sensitive and therefore dependent on
activation of Gi proteins. Activated Gi is able to inhibit adenylyl
cyclase as well as activate the Src family of tyrosine kinases
while liberated Gβγ activates phospholipase C-β (PLC-β) and
phosphoinositide-3 kinase (PI3K) ultimately leading to the
regulation of processes such as gene transcription, cell
migration, and cell adhesion (Fig. 1).
2.3. G protein independent signaling
Activation of the JAK/STAT pathway by CXCR4 has been
proposed to be G protein independent [66]. SDF induced the
transient association of JAK2 and JAK3 with CXCR4, leading
to the activation and nuclear translocation of a number of
STAT proteins. While JAK/STAT activation was G protein-
independent, pretreatment with PTX led to a prolonged
association of JAK with CXCR4 suggesting that G protein
Fig. 1. Signal transduction pathways and regulation of CXCR4. SDF binding to CXCR4 leads to the activation of multiple G protein-dependent signaling pathways,
resulting in diverse biological outcomes such as migration, adhesion, and transcriptional activation. Pathways activated and outcomes elicited may differ between
CXCR4+ cell types. Two potential G protein-independent pathways have been described. Tyrosine phosphorylation of CXCR4 results in the recruitment and activation
of the JAK/STAT pathway, while p38 and ERK activation has been shown to be partially dependent on arrestin-3. Following activation, GRK phosphorylation results
in the recruitment of arrestin 2/3 and subsequent internalization. CXCR4 is also ubiquitinated by AIP4 at the plasma membrane, which results in its sorting to and
degradation in lysosomes. However, a portion of the internalized receptor may also recycle back to the plasma membrane.
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[66].
The non-visual arrestins (arrestin-2 and-3, also called β-
arrestin-1 and-2) have classically been considered to shut off
signal transduction following receptor activation, a process
termed desensitization [94]. Indeed, lymphocytes isolated from
arrestin-3 knock out mice display attenuated desensitization and
enhanced G protein coupling of CXCR4 [95]. However, these
mice also display a decreased chemotactic response to SDF,
possibly due to the ability of arrestin-3 to promote signaling
[95]. In addition to signal termination, arrestins are able to act as
scaffolds for a number of signaling molecules [96,97]. These
interactions may serve to propagate signaling or even create a
platform to allow for activation of the proper signaling cascade
[98]. Consistent with these observations, it has been reported
that arrestin-2 and-3 enhance CXCR4-mediated ERK activation
[99] and arrestin-3 is involved in p38 activation and migration
following SDF stimulation [100]. Taken together, non-visual
arrestins may play a role in regulating CXCR4/Gi interaction as
well as SDF-promoted signaling and cell migration.2.4. Regulation of signaling
Three processes primarily regulate GPCRs: desensitization
(homologous and heterologous), internalization, and degrada-
tion. The process of homologous desensitization, or becoming
refractory to continued stimulation, is initiated by G protein-
coupled receptor kinase (GRK) phosphorylation of serine/
threonine residues of the third intracellular loop (TIL) or
cytoplasmic tail (C-tail) following receptor activation [94]. This
phosphorylation allows for the subsequent binding of arrestin-2
and/or arrestin-3, effectively uncoupling the receptor from
further G protein activation and often targeting the receptor for
internalization [94].
Upon SDF activation, CXCR4 is rapidly phosphorylated and
internalized [101–104]. Removing the 45 amino acid C-tail of
CXCR4, which contains 15 serine and 3 threonine residues,
eliminates agonist-promoted phosphorylation [101], enhances
receptor activity, and attenuates receptor internalization [103].
Truncation and alanine scanning mutagenesis has suggested
multiple regions in the CXCR4 C-tail as potential phospho-
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resulted in reduced SDF-promoted phosphorylation of CXCR4
as did truncation of the C-terminal 7 amino acids, which
removes serines 346, 347, 348, 351, and 352 (Fig. 2A) [102].
Recently, a phospho-specific antibody directed against phos-
pho-Ser339 also revealed increased phosphorylation of Ser339
following SDF stimulation [105]. Interestingly, increased
phosphorylation of Ser339 was also observed following EGF
or phorbol ester treatment [105], suggesting that this may be a
potential PKC phosphorylation site. To date, the GRKs
responsible for phosphorylation of CXCR4 have not been
identified, although GRK2 [99,102] and GRK6 [95,106] have
been implicated. Overexpression of GRK2 was able to enhance
SDF-mediated internalization of CXCR4, which was further
increased by the co-expression of arrestin-3 [99,102]. Interest-
ingly, GRK2 has also been suggested to negatively regulate
CXCR4 signal transduction at a level downstream of the
receptor, possibly via interaction with MEK [107]. Lympho-
cytes and neutrophils isolated from mice with a targeted
disruption of GRK6 showed enhanced CXCR4 function and a
lack of desensitization [95,106], which was not seen in cells
isolated from mice lacking GRK5 [95]. These data suggest that
there may be multiple kinases regulating CXCR4 in response to
SDF stimulation. As has recently been suggested for the
angiotensin [108,109], vasopressin [110], and β2-adrenergic
receptors [111,112], the coordinated action of these kinases may
be necessary for proper receptor regulation by dictating specific
interactions through alternative phosphorylation patterns.
Many GPCRs also undergo a process termed heterologous
desensitization, which is mediated by the activation of second
messenger dependent protein kinases such as PKA and PKC.Fig. 2. Amino acid sequence of the C-terminal tail of CXCR4. (A) The C-
terminal tail of CXCR4 contains 15 serine and 3 threonine residues. Truncation
and alanine scanning mutagenesis has identified multiple residues as potential
phospho-acceptor sites (highlighted in yellow) as well as those residues
important for degradation (highlighted in red). Evidence to date suggests that
multiple GRKs are responsible for homologous desensitization of CXCR4.
Additionally, multiple residues are potential PKC phosphorylation sites. (B)
Amino acid sequence of CXCR4 as a result of the various germline mutations
identified to date resulting in WHIM syndrome.Sequence analysis of CXCR4 shows that multiple serines in the
C-tail are potential PKC phosphorylation sites. Consistent with
this, direct activation of PKC using phorbol esters results in
phosphorylation [101] and internalization [102–104] of
CXCR4. Although the sites of phorbol ester induced phospho-
rylation of CXCR4 have not been completely determined, a
significant decrease in phorbol ester induced internalization was
observed when either Ser324 and Ser325 or Ser338 and Ser339
were mutated [104] while phorbol ester treatment induced
phosphorylation of Ser339 [105]. More physiologically relevant
stimuli that lead to PKC activation such as T or B cell receptor
engagement [113,114], formyl peptide receptor activation
[115,116], CXCR1 activation [117], CXCR2 activation [118],
or CCR5 activation [119] are also able to induce CXCR4
internalization.
Phosphorylation of tyrosine residues in CXCR4 has also
been observed following both SDF [66] and cytokine activation
[33], although the residues that are phosphorylated are currently
unknown. SDF-promoted tyrosine phosphorylation may pro-
mote the activation of the JAK/STAT pathway [66,120], while
cytokine-induced tyrosine phosphorylation may be a way of
promoting ligand-independent internalization of CXCR4 [33].
2.5. Internalization and degradation
Upon internalization, GPCRs can be recycled back to the
plasma membrane or sorted to the lysosome for degradation
[121]. CXCR4 can recycle back to the plasma membrane
following PKC-mediated internalization [103], however, the
receptor recycles poorly following SDF stimulation [122]. In
fact, CXCR4 has been shown to be ubiquitinated, sorted to the
lysosome, and degraded [123], a process mediated by the E3
ubiquitin ligase AIP4 [124]. Based on electrophoretic mobility
shift, the receptor is most likely mono-ubiquitinated on one of
three lysine residues (Lys327, Lys331, or Lys333) in the C-tail.
Mutation of these three residues to arginine eliminates
ubiquitination and degradation of the receptor [123]. Interest-
ingly, mutation of Ser330 to alanine partially inhibited
degradation of CXCR4 without affecting receptor internaliza-
tion while mutation of Ser324 and Ser325 partially inhibited
SDF-promoted internalization but completely disrupted degra-
dation [123]. Taken together, these data suggest that phosphor-
ylation of specific residues may dictate the fate of the receptor
following internalization.
3. CXCR4 dysregulation in disease
3.1. WHIM syndrome
Heterozygous mutations in the gene encoding CXCR4 leads
to a rare combined immunodeficiency characterized by warts,
hypogammaglobulinemia, recurrent bacterial infection, and
myelokathexis, known as WHIM syndrome [125,126]. WHIM
syndrome is currently the only immunological disease asso-
ciated with mutations to a chemokine receptor [125]. The
mutations identified to date (one frameshift and three nonsense
mutations) all truncate the C-terminal tail of CXCR4 (Fig. 2B)
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number of potential phosphorylation sites [127,128]. This leads
to the expression of a receptor with altered regulation.
Following activation, there is a lack of desensitization
[128,129], enhanced chemotaxis [128,130], an increase in
F-actin polymerization [129], enhanced calcium mobilization
[130], and a decrease in SDF promoted internalization
[129,130], although one report found no difference in calcium
mobilization or internalization [128].
Interestingly, WHIM syndrome has recently been reported in
two patients expressing a wild type CXCR4 [129]. Functional
assays using cells isolated from these patients revealed that,
consistent with classical WHIM cases, there was a lack of
desensitization and internalization of CXCR4 following SDF
stimulation. The lack of germline mutations in these receptors
suggests that there is a change in some downstream regulator
such as a GRK or arrestin. Interestingly, mice lacking either
GRK6 [95,106] or arrestin-3 [95] have enhanced receptor
function in response to SDF stimulation, similar to those seen in
WHIM syndrome, suggesting that these two proteins may play a
primary role in regulating CXCR4.
3.2. Cancer
The expression of CXCR4 has been detected in 23 different
cancers of various origins [131] and is the most common
chemokine receptor expressed on cancer cells [23]. The
expression of CXCR4 on hematopoietic malignancies is not
surprising given the critical role of the receptor in development
of these cells [11,15,132–134]. However, in a variety of other
cancers, CXCR4 expression is enhanced compared to the
adjacent normal tissue, which may have little or no CXCR4
[135–137]. A potential underlying mechanism for this may
result from changes that occur within the vasculature or O2
carrying capacity of cells leading to hypoxic conditions during
tumor progression [138]. Hypoxia induces the activation of
hypoxia inducible factor 1 (HIF-1) which in turn promotes
expression of a number of target genes [138] including CXCR4
[139–141]. Further evidence regarding the role of HIF-1 came
from studies of the tumor suppressor von Hipple Lindau (VHL).
Inactivating mutations of VHL, which normally targets HIF-1
for degradation, account for the increased CXCR4 expression in
renal cell carcinomas [139–141].
A number of other factors also have the ability to enhance
CXCR4 expression specifically during cancer progression. For
example, vascular endothelial growth factor (VEGF) [142] or
activation of nuclear factor kappa B (NF-κB) [143] enhances
CXCR4 expression in breast cancer promoting invasion and
metastasis, respectively. Additionally, it has been shown that
CXCR4 expression can be induced by the oncoproteins PAX3-
FKHR [144,145] and RET/PTC [146]. CXCR4 expression as a
result of the PAX3-FKHR fusion leads to enhanced migration
and adhesion of rhabdomyosarcoma cells [145], while RET/
PTC induced expression enhanced the transforming ability of
breast cancer cells [146]. Increased cell surface expression of
CXCR4 may also be the result of altered regulation,
independent of effects on transcription/translation. Ubiquitina-tion of CXCR4 is a modification regulating the expression of
CXCR4 post-translationally [123,124]. It has been found that
breast cancer cells that are HER2/neu positive have increased
expression of CXCR4 as a result of inhibition of receptor
ubiquitination [147]. Expression of AIP4, the E3 ubiquitin
ligase responsible for ubiquitination of CXCR4 [124], was able
to reverse this effect [147]. Moreover, the recent finding that
cytokine-independent survival kinase (CISK) associates with
and inhibits AIP4 function [148] provides a potential link
between HER2 positive breast cancers and the attenuated
degradation of CXCR4 [147]. It will be interesting to examine if
altered CXCR4 ubiquitination is a global phenomenon in
CXCR4-overexpressing cancers or if this effect is specific to
HER2/neu expressing cancers.
It is expected that the functional consequence of CXCR4
expression on cancer cells would be varied based on the
numerous roles of the CXCR4-SDF signaling axis. For
example, the combination of CXCR4 expression and interaction
with stromal or nurse-like cells in chronic lymphocytic
leukemia [149] and multiple myeloma [150] may account for
resistance to spontaneous/drug induced apoptosis and cell
adhesion-mediated drug resistance, essentially providing a
protective niche. Tumor progression is also affected by
CXCR4–SDF-1 signaling through the induction of tumor-
associated integrin activation and signaling [151].
Since SDF is a chemokine, an attractive hypothesis is that
CXCR4 expression correlates with metastasis. Consistent with
this, activation of CXCR4 stimulates the production of matrix
metalloproteases [152–155] potentially facilitating the ability of
cancers to egress from the primary tumor site. Furthermore,
SDF signaling is also able to enhance integrin activity [156–
158] enhancing cell adhesion under flow conditions. Upon
entering the blood or lymphatic systems, if CXCR4 truly
mediates metastasis, tumors would preferentially migrate and
adhere to areas that highly express SDF-1. Breast cancer
follows this distinct pattern of metastasis, namely to lymph
nodes, lung, liver, and bone marrow all of which highly express
SDF-1 [135,159]. Accordingly, neutralizing antibodies to
CXCR4 [135] or siRNA knock down [160,161] inhibit
metastasis and growth of breast cancer cells. Other cancers,
such as small cell lung cancer, thyroid, neuroblastoma,
hematological and hepatic malignancies also metastasize to
areas with high SDF-1 expression [162–166]. In spite of this
evidence, studies attempting to correlate expression with
metastatic potential have yielded mixed results. Whereas
CXCR4 expression increased with aggressiveness of prostate
tumors [137] there was not a significant correlation of CXCR4
expression and distant breast cancer cell metastasis [167],
although the extent of nodal metastasis was greater in cells
expressing high levels of CXCR4 compared to those with lower
levels [167]. Recently, CXCR4 expression on hepatocellular
carcinoma was suggested to correlate with local tumor
progression, lymphatic and distant metastasis, as well as
negatively impact the 3-year survival rate of these patients
[166].
On the other hand, cancers such as lymphomas, glioma,
ovarian, and pancreatic have a high expression of SDF-1 at the
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mally express CXCR4 [172]. Thus, the CXCR4–SDF-1
interaction could be retaining tumor cells that originate at
these sites, analogous to the retention of B-cells and neutrophils
in the bone marrow during development. Epigenetic mechan-
isms that negatively regulate the expression of SDF or CXCR4
may be necessary in order for metastasis to occur. One example
is DNA methylation, a modification typically associated with
inactivation of tumor suppressors [173]. It has recently been
shown that methylation of the SDF promoter in colonic
epithelium promotes metastasis of these tumors [174]. The
CXCR4 promoter is also methylated in a number of pancreatic
cancers, decreasing mRNA and protein levels [175]. Though
not addressed in the study, this may be a mechanism that allows
pancreatic cancers to metastasize from these sites.
As detailed above, the C-tail is absolutely critical for proper
regulation of CXCR4. Interestingly, expression of a C-tail
truncated mutant of CXCR4 in MCF-7 mammary carcinoma
cells led to an epithelial-to-mesenchymal transition [176].
Oligomicroarray analysis showed that there was a down
regulation of E-cadherin and Zonula occludens, thereby
disrupting cell-to-cell contacts, with a concomitant increase in
ERK activation. There was also an increased expression of a
number of growth factor receptors. While there have been no
cancers described as a result of truncation of CXCR4, this may
give insight into the signaling pathways critical for cancer
progression and metastasis.
Recent evidence also suggests that, in some breast cancers,
receptor expression and functional activity are not linked [177].
Examining a variety of breast cancer cell lines, ranging from
untransformed but immortalized to highly invasive, it was
concluded that receptor expression alone does not lead to the
acquisition of an invasive phenotype. Specifically, it was
speculated that there were alterations in G protein coupling to
the receptor. Untransformed or transformed non-invasive cells
were not able to properly couple to Gi, and therefore, were not
able to elicit Ca2+ mobilization, ERK activation or migration;
signaling pathways conserved in the invasive lines. Interest-
ingly, as B cells develop into mature cells, they progressively
lose the ability to respond to SDF-1 even though surface
expression of CXCR4 remains relatively high [178,179].
However, as they further differentiate into plasma cells, they
regain responsiveness to SDF [180]. The underlying mechan-
isms regulating this phenomenon in B cells are currently not
known, though similar mechanisms may be occurring as a result
of the transition to a more malignant phenotype in these breast
cancer cells.
3.3. Summary
In this review, we have highlighted what is currently known
regarding the regulation of CXCR4 and the consequences of
dysregulation. Given the multifaceted role CXCR4 plays in
diverse processes from development to cancer metastasis,
CXCR4 is a very intriguing therapeutic target. An ample
body of work has been generated in delineating potential
pathways that mediate specific effects (e.g., leading tometastasis), however, a detailed basic understanding of receptor
regulation is lacking. Understanding the precise mechanisms
regulating CXCR4 function at the receptor level should provide
insight into attractive therapeutic targets in this pathway.
Furthermore, this will allow for translational research opportu-
nities to dissect the specifics of how receptor regulation is
altered in disease.
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